A Agilent Technologies Inc.

Agilent Launches Partnership with Delaware State University to Advance Diversity in Science, Technology, Engineering and Math (STEM) Fields

Agilent Technologies Inc. (NYSE: A) is launching a partnership with Delaware State University (DSU), a leading historically Black university, to increase the share of underrepresented students entering STEM fields, a central mission of the company’s philanthropic work through the Agilent Foundation.

Agilent will donate $1 million in addition to new lab instrumentation to help DSU expand educational opportunities and advance research in applied chemistry, biological sciences, food science, molecular and cellular neuroscience, and related disciplines. Agilent’s support will also contribute to building research capacity of a consortium of historically Black colleges and universities (HBCUs) in the mid-Atlantic region led by Delaware State.

“DSU has a tremendous pool of talented STEM students,” said Agilent President and CEO Mike McMullen. “This partnership will help us provide direct support to these students and encourage more scholars at HBCUs across the mid-Atlantic to consider opportunities at Agilent and within the broader life sciences sector.”

Agilent’s donation comes as DSU breaks ground on a new 24,000-square-foot building for its College of Agriculture Science and Technology (CAST), which includes space for new labs.

“Many believe that this is a renaissance moment for HBCUs. It’s not,” said DSU President Dr. Tony Allen. “We’ve been doing the work for 175 years—building the most useful pipeline for African Americans to the American middle class and breaking new ground in every field of human endeavor. Great companies like Agilent understand the work and are connecting with our system for the long term, a system still producing 25% of all the Black STEM graduates in our country. Our partnership with Agilent is about making the HBCU difference today, tomorrow, and for generations to come.”

The donation will fully fund 21 graduate and undergraduate students pursuing STEM degrees. Agilent is also providing analytical lab instrumentation, supplies, services, and other infrastructure to equip CAST’s new lab space.

“DSU is making important contributions to the STEM fields, and this donation will help ensure this historically underinvested and underrepresented community is getting the resources needed to have an even greater impact,” said Gregory MacKenney, the vice president of Agilent's instrument supplies business, and an alumnus of Morgan State University and co-founder of Agilent’s networking group for Black employees.

Agilent will also provide mentorship opportunities for DSU students with Agilent scientists, engineers, and researchers and will help fund DSU’s summer internship program for STEM students.

To further support the partnership, Agilent is double-matching employee donations to HBCUs through the end of the year. The investment in HBCUs is part of Agilent’s broader philanthropic work, which focuses on increasing the pipeline of early-career professionals entering the life-sciences sector and addressing climate change and other environmental issues. It also advances the goals of Agilent’s .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on , and .

EN
29/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch